Company profile

CORCEPT THERAPEUTICS INC

NASDAQ:CORTBiotechnology: Pharmaceutical Preparations

Drug pipeline (4)

AssetStageRevenueTrialsStatus
LIFYORLI (COPACKAGED)approved$47.6MQ2 202619approved
KORLYMapproved—19approved
DAZUCORILANTphase2—4active
MIRICORILANTphase2—12active

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (67)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00698022phase1completed2008-11-012009-02-01Corcept TherapeuticsA 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
NCT06108219phase2completed2023-10-252026-02-13Corcept TherapeuticsA Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT00752843phase1completed2008-09-012008-11-01Corcept TherapeuticsA Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers
NCT03067376phase1completed2016-08-012016-09-01Corcept TherapeuticsA Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body
NCT04524403phase2completed2020-09-092022-07-29Corcept TherapeuticsA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

FDA applications (2)

ApplicationApprovedTypeApplicantProducts
NDA 2206412026-03-25NDACORCEPT THERAPEUTICS INC
NDA 2021072012-02-17NDACORCEPT THERAPEUTICS INC